8-K: InMed Pharmaceuticals Unveils Promising Preclinical Alzheimer's Data for INM-901

InMed Pharmaceuticals announced new preclinical data for its INM-901 program, demonstrating multi-modal activity and therapeutic potential in Alzheimer's disease, to be presented at the Alzheimers Association International Conference 2025.

Summary

• InMed Pharmaceuticals Inc. is presenting new preclinical data from its INM-901 program at the upcoming Alzheimers Association International Conference (AAIC) 2025, scheduled for July 27-31, 2025, in Toronto, Canada.
• The data, from a long-term study in a 5xFAD Alzheimer's disease mouse model, will be presented in a scientific poster titled 'Therapeutic Potential of INM-901 in Mitigating Alzheimers Disease Pathology: Insights from a Long-term 5xFAD Mouse Model Study'.
• The study evaluated INM-901 in subjects with more advanced disease and a longer treatment duration to validate and expand upon previous findings.
• Key findings include dose-dependent trends towards a return to non-diseased baseline in hippocampal RNA expression for genes associated with inflammation, the endocannabinoid system, synaptic dysfunction, oxidative stress, and apoptosis.
• Treatment with INM-901 resulted in a significant reduction in inflammatory biomarkers such as IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, and NfL, suggesting a dose-dependent therapeutic effect in neuroinflammation.
• Amyloid-beta (Aβ) immunoreactivity was reduced in a dose-dependent manner, and MAP2, a protein involved in neurite outgrowth and signal transduction, was partially restored with INM-901 treatment.
• Behavioral improvements were observed, with cognitive function, anxiety-related behavior, and sensory responsiveness being restored or approaching normal following INM-901 treatment.

Sentiment

Score: 8

Explanation: The filing presents highly positive preclinical data for a drug candidate targeting Alzheimer's disease, a condition with significant unmet medical needs. The results show multi-modal activity and improvements across several key biological and behavioral markers, indicating strong potential. While still preclinical, the consistency and breadth of the positive findings are very encouraging.

Positives

• INM-901 demonstrated multi-modal activity in preclinical studies, targeting multiple biological pathways in Alzheimer's disease.
• The study showed a dose-dependent trend towards restoring hippocampal RNA expression to non-diseased baseline, indicating positive effects on gene expression related to inflammation and cell health.
• Significant reduction in key inflammatory biomarkers (IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL) suggests strong anti-inflammatory action in neuroinflammation.
• Amyloid-beta (Aβ) immunoreactivity, a hallmark of Alzheimer's pathology, was reduced in a dose-dependent manner.
• MAP2, a protein crucial for neuronal structure and function, was partially restored, indicating potential for neuronal regeneration and enhanced connectivity.
• Behavioral improvements were observed, including restoration or near-restoration of cognitive function, anxiety-related behavior, and sensory responsiveness.
• INM-901 exhibits neuroprotective qualities by significantly reducing amyloid-beta-induced cell death.
• The data aligns with previous findings, validating and expanding on the potential of INM-901 as a multi-targeted treatment candidate for Alzheimer's disease.

Risks

• Forward-looking information inherently involves numerous risks, uncertainties, and assumptions, many of which are beyond the company's control.
• Statements regarding the potential efficacy of INM-901, its ability to treat Alzheimer's, and its marketability and uses are subject to known and unknown risk factors.
• Actual results, performance, or achievements could be materially different from any future results, performance, or achievements expressed or implied by the forward-looking information.
• A complete discussion of risks and uncertainties is disclosed in the company's Annual Report on Form 10-Q, Item 1A of the Quarterly Report for the period ended March 31, 2025, and other SEC filings.

Future Outlook

The company's forward-looking statements indicate a focus on the potential efficacy of INM-901, its ability to treat Alzheimer's disease, and its future marketability and uses. The ongoing preclinical data continues to build evidence for INM-901 as a multi-targeted treatment candidate.

Management Comments

• Dr. Eric Hsu, SVP, Preclinical Research & Development at InMed, commented that 'The latest data continues to build on mounting preclinical evidence of the potential of INM-901 as a multi-targeted treatment candidate for Alzheimers disease. INM-901 demonstrates a differentiated therapeutic approach in mitigating Alzheimers pathology and we are excited to share the results from this study with the Alzheimers disease community at the AAIC.'

Industry Context

Alzheimer's disease represents a significant global health challenge with a high unmet medical need. The presentation of promising preclinical data for a multi-targeted small molecule drug candidate like INM-901 at a premier global event like the Alzheimers Association International Conference (AAIC) highlights ongoing efforts in the pharmaceutical industry to develop novel treatments. A multi-modal approach, targeting various pathological features of AD, is increasingly recognized as a promising strategy given the complexity of the disease.

Stakeholder Impact

• Shareholders: Positive preclinical data could lead to increased investor confidence and potential share price appreciation due to the promising development in a high-value therapeutic area.
• Patients with Alzheimer's Disease: The development of INM-901 offers potential hope for a new, multi-targeted treatment option for a debilitating disease with limited effective therapies.
• Scientific and Medical Community: The presentation of new data at a leading international conference contributes to the broader understanding of Alzheimer's pathology and potential therapeutic strategies.

Next Steps

• Presentation of the scientific poster at the Alzheimers Association International Conference (AAIC) 2025 from July 27-31, 2025.
• The presentation poster will be made available on InMed's website following the conference.

Key Dates

Recommendation

The preclinical data for INM-901 is highly encouraging, demonstrating multi-modal activity and significant positive effects across various biological and behavioral markers in an Alzheimer's disease model. While still in early stages of development, the consistent and robust findings for a disease with high unmet medical needs suggest strong future potential. This positive development warrants a 'buy' recommendation for investors with a long-term horizon and an appetite for biotech risk, as successful progression through clinical trials could lead to substantial value creation.

Keywords

Alzheimer's disease, INM-901, preclinical data, neuroinflammation, amyloid-beta, cognitive function, pharmaceutical, drug development, InMed Pharmaceuticals, AAIC